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Summary
MicroRNAs-221 and -222 are highly upregulated in several solid tumors, including melanomas. We demon-
strate that the proto-oncogene ETS-1, involved in the pathogenesis of cancers of different origin, is a tran-
scriptional regulator of miR-222 by direct binding to its promoter region. Differently from 293FT cells or early
stage melanomas, where unphosphorylated ETS-1 represses miR-222 transcription, in metastatic melanoma
the constitutively Thr-38 phosphorylated fraction of ETS-1 induces miR-222. Despite its stepwise decreased
expression along with melanoma progression, the oncogenic activity of ETS-1 relies on its RAS⁄RAF⁄ERK-
dependent phosphorylation status more than on its total amount. To close the loop, we demonstrate ETS-1
as a direct target of miR-222, but not miR-221, showing the novel option of their uncoupled functions. In addi-
tion, a spatial redistribution of ETS-1 protein from the nucleus to the cytoplasm is also evidenced in advanced
melanoma cells. Finally, in vivo studies conﬁrmed the contribution of miR-222 to the increased invasive
potential obtained by ETS- silencing.
Introduction
Cutaneous melanoma is one of the most aggressive
neoplasms. Although surgical excision is mostly a deﬁni-
tive treatment at the early stages of the disease, at
present, standard treatments are ineffective after
metastatic dissemination (Chudnovsky et al., 2005;
Gray-Schopfer et al., 2007). The identiﬁcation of new
suitable prognostic and diagnostic markers and possibly
therapeutic targets has been thoroughly researched
(Gremel et al., 2009).
MicroRNAs (miRNAs) are a family of small, non-cod-
ing RNAs able to post-transcriptionally repress gene
expression by pairing to the 3¢UTR of target mRNAs
(Calin and Croce, 2006). MiRNAs are involved in all the
main biological processes and their aberrant deregulated
expression has functional implications in tumor develop-
ment (Inui et al., 2010). The miR-221 and -222 have
Signiﬁcance
MiR-221 and -222 have been reported as important regulators of tumor cell proliferation, migration and
invasion in cancers of different origins, including melanoma. Growing evidence suggests their inhibition
as a promising option for a novel therapeutic approach, particularly relevant in melanoma still lacking
successful treatments. However, a complete knowledge of miR-221⁄-222 actual targets and downstream
pathways is obligatory before opening this door. Here, we reveal the existence of a novel ETS-1MmiR-
222 circuitry in which both miR-222 and the phosphorylated activating portion of ETS-1 are relevant to
melanoma progression.
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tently in melanoma (Felicetti et al., 2008; le Sage et al.,
2007; Medina et al., 2008). Indeed, they enhance tumor-
igenicity in non-small cell lung cancer (NSCLC) and he-
patocarcinoma cells (HCC) by targeting PTEN and
TIMP3 tumor suppressors; in turn, they are activated by
c-MET through the AP-1 transcription complex (Garofalo
et al., 2009). We have reported that miR-221 and -222
act on melanoma progression through multiple onco-
genic pathways downregulating p27Kip1 and c-KIT
receptors, leading to enhanced proliferation and blocking
the differentiation of melanoma cells (Felicetti et al.,
2008).
Looking for new miR-221⁄-222-dependent target
genes, we focused on the proto-oncogene ETS-1, the
founding member of the family of ETS transcriptional
factors known to be involved in the pathogenesis of
cancers of different origin. However, the role of ETS-1
in melanoma is far from being clearly demonstrated.
ETS-1 protein regulates many target genes by func-
tionally or physically interacting with several transcrip-
tion factors whose combinations lead to either gene
activation or repression (Dittmer, 2003). ETS-1 p51 pro-
tein binds to purine-rich DNA sequence, containing a
conserved GGAA⁄T core sequence, through its DNA
binding domain. ETS-1 is also post-translationally regu-
lated in that RAS increases its transcriptional activity
through ERK1⁄2 (Yang et al., 1996), which phosphory-
lates ETS-1 at a single threonine (T38) within the N-ter-
minal domain (Seidel and Graves, 2002). Conversely,
CaMKII is able to mediate calcium-dependent inactiva-
tion of ETS-1 DNA binding by phosphorylating the regu-
latory exon VII domain of ETS-1 (Cowley and Graves,
2000; Pognonec et al., 1988).
We selected ETS-1 among many putative miR-221⁄-
222-regulated target genes based on the good score
reported for the main speciﬁc sites using TargetScan,
microRNA and PicTar, which have been speciﬁcally
developed for the identiﬁcation of the actual targets of
microRNA. Besides that, and possibly more importantly,
we focused on the functional role of ETS1, bearing in
mind that in melanoma, basic ﬁbroblast growth factor
(bFGF) constitutive activation is the main initiating factor
of the MAPK-ERK-Ets1⁄2 signaling cascade (Care ` et al.,
1996; Squarzoni et al., 2011). ETS-1 is expressed in mel-
anocytes migrating from the neural crest during embryo-
genesis and in normal adult melanocytes, but its role in
malignant melanomas appears controversial. ETS-1 has
been reported either as a valuable diagnostic⁄prognostic
marker (Rothhammer et al., 2004) or as molecule with
no clear association with clinical outcome (Torlakovic
et al., 2004).
Here we demonstrate the existence of an ETS-
1MmiR-222 circuitry relevant to melanoma progression.
We identify ETS-1 as a transcriptional regulator of miR-
222, by direct binding to its promoter region, showing
its functional shift, from negative to positive regulator,
in early and advanced melanoma cells, respectively.
Unlike low grade malignant cells, where ETS-1
represses miR-222 transcription, in metastatic melano-
mas ETS-1 and miR-222 appear directly interconnected
by a deregulated feedback loop whereby the persistent
activation of the MAPK-ERK1⁄2 cascade leads to Thr-38
phosphorylation of ETS-1 and miR-222 induction, in turn
increasing proliferation and tumor malignancy (Felicetti
et al., 2008). In addition, we show that ETS-1 is directly
targeted by miR-222, but not by miR-221, indicating the
option of miR-221 and -222 uncoupled functionalities.
Considering the role of c-JUN in miR-221⁄-222 activation
(Garofalo et al., 2009), we suggest an ETS-1⁄c-JUN col-
laboration where ETS-1 seems to ﬁne tune miR-222 as
well as c-JUN itself (Goldberg et al., 1994). Finally,
based on our previous results showing the tumor-sup-
pressor role of the promyelocytic leukemia zinc ﬁnger
(PLZF) product in melanoma, we examined the possibil-
ity of an ETS-1⁄PLZF coordinated function.
Results
ETS-1 expression in melanoma
We evaluated ETS-1 expression in a panel of melanoma
cell lines at different stages of progression, including pri-
mary vertical growth phase (VGP) melanomas, as well
as subcutaneous and lymph-node metastases (Felicetti
et al., 2004). Traditional and qRT-PCR as well as Wes-
tern blot analyses on nuclear extracts showed that all
these melanoma cell lines expressed ETS-1 at levels
inversely related to melanoma malignancy. In particular,
primary and metastatic melanomas expressed high and
low amounts of ETS-1 at mRNA (Figure 1A) and protein
levels (Figure 1B), respectively. To rule out any possible
artifactual result due to in vitro cell culture, this expres-
sion pattern was conﬁrmed in early passage cells
obtained from melanoma bioptic samples (Figure 1C).
Note that a high level of ETS-1 mRNA and protein was
detected in normal human melanocytes (Figure 1A).
ETS-1 phosphorylation
Considering that the transcription factor ETS-1 regulates
many tumor-promoting factors, we reasoned that its
downregulation along with melanoma progression can-
not explain its presumed oncogenic role, which might
rather correlate with an increased activity due to anoma-
lous post-translational modiﬁcations. ETS-1 molecules
harbor two phosphorylation sites, threonine-38 (T38)
and an array of serines within the exon VII domain (4S:
S251, S257, S282, S285). Phosphorylation at T38 by
ERK1⁄2 activates ETS-1, whereas phosphorylation of
the exon VII 4S domain by CaMKII or MLCK reduces
ETS-1 DNA binding and transcriptional activity (Dittmer,
2003). To test our hypothesis, we analyzed the level of
ETS-1 activating phosphorylation by a speciﬁc anti-
P-T38-ETS-1 antibody. WB analysis (Figure 2A) showed
a signiﬁcant inverse correlation between total ETS-1 and
Mattia et al.
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gression. As shown (Figure 2A and Supporting Informa-
tion Figure S1) melanocytes and primary melanomas,
expressing high levels of total ETS-1, displayed a barely
or undetectable phosphorylated fraction, whereas most
of the ETS-1 protein was activated through T38-phos-
phorylation in metastatic melanomas. These results cor-
related with the different phosphorylation status of
ERK1⁄2. Considering the possible functional relevance
of ETS-1 cellular topographic distribution, equal amounts
of cytoplasmic and nuclear extracts obtained from
Me1007 and A375M, as representatives of primary
and advanced melanoma cell lines, were analyzed by
immunoblot. Despite a signiﬁcant amount of ETS-1 in
the cytoplasm of both primary and advanced tumor
cells (Figure 2B), the T38-phosphorylated fraction in the
nuclear extracts was clearly visible only in the A375M
metastatic cell line (Figure 2B).
Confocal immunoﬂuorescence analysis conﬁrmed the
different level of P-T38-ETS-1 in primary versus
advanced melanomas. In Me1007 primary melanoma
cell line, the low level of nuclear P-T38 ETS-1 (red)
made it difﬁcult to detect when merged with the
strongly stained total ETS-1 (green) (Figure 2C, left).
Conversely, in the metastatic A375M cell line, a nuclear
bright and scattered signal of P-T38 ETS-1 (red) colo-
calized in the merging picture (orange spots) with the
slight nuclear portion of total ETS-1 (green). As evident
in these metastatic cells most of the unphosphorylated
ETS-1 is contained in the cytoplasm (Figure 2C, right).
Conversely, the considerable level of phosphorylation
of serines at exon VII did not show any clear modulation
among melanomas at different stages of disease (not
shown).
ETS-1 level is downregulated by miR-222
Based on the inverse correlation between ETS-1 and
miR-221⁄-222 expression patterns (Figure 3A) and on
bioinformatics analyses (TargetScan, RNAHybrid), pre-
dicting the presence of one conserved binding site in
the 3¢ UTR of ETS-1, we tested, using a luciferase
assay, whether miR-221⁄-222 were able to directly tar-
get ETS-1. The ETS-1 3¢UTR, encompassing the seed
sequence theoretically recognized by miR-221 and -222,
was cloned downstream to the luciferase open reading
frame in a modiﬁed pGL3 promoter vector. Cotransfec-
tion experiments were performed in the 293FT cell line.
We avoided the use of the whole 3.6 kb 3¢UTR in the
transfection assays in order to exclude a series of ade-
nylate- and uridylate-rich repeats which may be involved
in mRNA stability and translational regulation (Chen and
Shyu, 1995). As shown in Figure 3B, transfections of
miR-222 in the presence of ETS-1 3¢UTR induced a sig-
niﬁcant decrease of the luciferase activity (roughly 50%
less than non-targeted control sequence). Surprisingly,
the effect induced by cotransfection of miR-221 was
negligible, suggesting that the coordinated function
reported for miR-221⁄-222 in the regulation of p27Kip,
c-KIT (Felicetti et al., 2008) and other target genes
(Garofalo et al., 2009) can be uncoupled. The control,
cotransfection of ETS-1 3¢UTR with a non-targeting
sequence as well as of ETS-1-mutated 3¢UTR with miR-
221⁄-222, did not show any repression in luciferase
activity, conﬁrming the speciﬁcity of such interactions
(Figure 3B). ETS-1 downregulation was conﬁrmed at
both mRNA and protein levels in miR-222-transduced
Me1007 and Me1402⁄R primary melanoma cell lines
(Figure 3C,D). In agreement with the luciferase results,
overexpression of miR-221 did not show signiﬁcant
effects on ETS-1 (Figure 3C,D). The reverse effect on
ETS-1 regulation was conﬁrmed in Me665⁄1 and
A375M metastatic melanomas by miR222-speciﬁc anta-
gomir transfection. Western blot analysis demonstrated
A
B
C
Figure 1. ETS-1 expression in normal human melanocytes and
melanomas. (A) qRT-PCR and (B) Western blot analyses of
stabilized melanoma cell lines at different stage of progression.
A representative WB is shown. Normal human melanocytes are
included as a normal reference and actin as a housekeeping
loading control. (C) qRTPCR analysis of melanomas at early in vitro
passages. qRT-PCR data represent the average ± SD of at least
three separate experiments.
ETS-1-miR-222 circuitry in metastatic melanoma
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compared with either antagomir-221 or the non-relevant
antagomir-133 (Figure 3E). These results indicate that
miR-222 is a true regulator of ETS-1 expression.
ETS-1 regulates miR-222 transcription
We reckoned that the increased level of P-T38 ETS-1
might be functional for growth and malignancy of cancer
cells. Since we evidenced a direct relation between
miR-221⁄-222 levels and the P-T38 form of ETS-1 in
melanoma progression (see Figure 3A), we hypothe-
sized that this regulation could be achieved through a
miR222-ETS-1 loop, where miR-222 diminished the ETS-1
level, but the residual P-T38 ETS-1-activated fraction
was in turn able to induce miR-222 transcription. To
prove this hypothesis, we looked for ETS-1 binding sites
(EBS) in the 0.6 kb sequence upstream to pre-miR-
222⁄-221 (MATINSPECTOR software – http://www.genom-
atix.de) (Figure 4A). To test whether such putative EBS
were truly functional, we performed a series of pro-
moter luciferase assays. The sequence from )555 to +1
nt (containing )203 and )407 ETS-1 BS, named BS1
and BS2, respectively), as well as the shorter fragment
from )400 to +1 nt (only containing )203 ETS-1 BS1)
were cloned in a promoter-less pGL vector and cotrans-
fected with empty or ETS-1-containing vectors at ﬁrst in
the highly transfectable 293FT cells (Figure S2) and then
in Me1007 and A375M, as representative primary and
metastatic melanoma cell lines (see Figure 4B).
A 30–45% ETS-1-dependent reduction of the lucifer-
ase activity was observed in the 293FT cells, likely due
to ETS-1 binding to the miR-222 regulatory sequences.
The introduction of point mutations in each core-binding
site restored the luciferase levels totally or partially
when mutations were in the BS1 ()203) or BS2 ()407)
sites, respectively (Supporting Information Figure S2A).
This suggests a different role⁄hierarchy for these two
binding sites and⁄or the presence of interacting activa-
tors in the )555⁄)400 region. The longer )555⁄+1 frag-
ment seems to induce a transcriptional activity higher
than the shorter )400⁄+1 fragment (not shown).
To close the loop, ETS-1 would be expected to regu-
late miR-222 and perhaps miR-221. To test this, 293FT
cells were transiently transfected with the ETS-1-
expressing vector (Figure S2B, left) and the level of both
endogenous miR-221 and -222 was evaluated by qReal-
time PCR at early as well as late time points (from 4 to
48 h) (Figure S2B, right). A signiﬁcant stepwise
decrease of miR-222 followed ETS-1 transfection. In
contrast, no clear modulation of miR-221 was observed,
conﬁrming the ﬁdelity of the miR-222-ETS-1 liaison
(Figure S2B, right). Western blot conﬁrmed the lack of
ETS-1 and ERK 1⁄2 phosphorylation (Figure S2C).
A similar ETS-1-dependent repressive function was
observed when early stage Me1007 melanoma,
expressing high levels of barely or unphosphorylated
ETS-1, was used as a recipient for the promoter lucifer-
ase assays. Dsi-ETS-1 cotransfection, in the presence of
AB
C Figure 2. Analysis of ETS-1
phosphorylation at Thr-38. (A)
Representative Western blot of ETS-1 and
its P-T38-fraction, ERK1⁄2 and P-ERK1⁄2
in four differently staged melanoma cell
lines. (B) Nuclear and cytoplasmic extracts
of Me1007 and A375M, shown as primary
and metastatic representative melanomas.
Actin, nucleolin and tubulin have been
included as loading controls. (C) Confocal
immunoﬂuorescence analysis with anti-
ETS-1 (green staining) and anti-P-T38-ETS-1
(red staining) antibodies assessing the
different levels and distribution of total
ETS-1 and T-38 phosphorylated fraction in
the primary Me1007 and metastatic
A375M melanoma cell lines.
Mattia et al.
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ﬁrmed the ETS-1 negative regulation on miR-222 tran-
scription (Figure 4B). In view of its lower activity we did
not include the shorter promoter fragment ()400⁄+1).
Notably, when the above cotransfection experiments
were run in the A375M metastatic melanoma cell line, a
substantially different picture was seen with ETS-1-
inducing miR-222 promoter-driven luciferase (Figure 4C).
A twofold induction was obtained by transfecting either
the short or the long fragments containing one (BS1) or
two (BS1 and BS2) ETS-1 binding sites, respectively.
This induction was totally abrogated when the BS1 site
was mutated either in the long or the short fragments
of miR promoter. In contrast, BS2 disruption only
AB
CD E
Figure 3. ETS-1 regulation by miR-221 and⁄or -222. (A) miR-221 and -222 expressions are inversely or directly correlated with ETS-1 or its P-
T38 fraction in melanoma progression. Data were obtained by densitometric analysis of representative Western and Northern blots (Figure 1,
2A, S1 and not shown); in each curve the highest value is reported as 100%. (B) Luciferase (LUC) reporter assay (columns of a minimum of 3
experiments, bars ± SD) performed by cotransfecting miR-221 and⁄or miR-222 in the presence of the LUC reporter gene linked to ETS-1
3¢UTR. As controls, mutated 3¢UTR sequences and a non-targeting oligomer were also included. **P < 0.01. Evaluation by qRT-PCR (C) and
WB (D) of ETS-1 expression in Me1007 and Me1402⁄R melanomas transduced with miR-221, miR-222 or control Tween vector. (E) WB
analysis of ETS-1 in antagomir-treated A375M and Me665⁄1 metastatic cell lines. Antagomir-133 represents an irrelevant negative control.
miR-221⁄-222 and antagomir oligos were utilized at 150 and 200 nM, respectively.
A
B C
DE
Figure 4. ETS-1 involvement in miR-221
and⁄or miR-222 transcriptional regulation.
(A) Schematic depiction of the genomic
region upstream of pre-miR-222. BS1 and
BS2 indicate ETS-1 putative binding sites,
and horizontal arrows the direction of
microRNA transcription. (B) Promoter
luciferase assays performed either in the
presence of Dsi-ETS-1 (200nM) or ETS-1
in Me1007 primary and (C) A375M
metastatic melanoma cell lines,
respectively. (D) Evaluation of miR-222
levels by qRT-PCR in Dsi-ETS-1 or ETS-1-
transfected cells compared with controls.
(E) Chromatin immunoprecipitation assays
in Me1007 (left) and A375M cells (middle
and right) with anti-ETS-1 or anti-P-T38-
ETS-1 antibodies (right).).*P < 0.05;
**P < 0.01.
ETS-1-miR-222 circuitry in metastatic melanoma
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ing to these results, qRealtime PCR showed that miR-
222 upregulation was a consequence of either ETS-1
silencing in primary melanomas or ETS-1-enforced
expression in metastatic melanomas (Figure 4D). To ver-
ify direct binding of ETS-1 to BS1 and BS2 on miR-221⁄-
222 promoter, we carried out chromatin immunoprecipi-
tation (ChIP) assays in Me1007 and A375M melanomas
(Figure 4E). ChIP assays of both cell lines showed a
signiﬁcant ETS-1 binding at the analyzed sites (BS1 and
BS2), whereas no chromatin enrichment was observed
in control reactions immunoprecipitated with an irrele-
vant antibody. Moreover, in the A375M metastatic cells
we also demonstrated the binding competence of the
Thr38 phosphorylated fraction of ETS-1 (Figure 4E,
right). The above results support the view that ETS-1
has different activities on miR-222 promoter depending
on cell context and, ultimately, its different phosphory-
lated status, as exempliﬁed by the comparison between
primary and advanced melanomas (Figure 4B,C).
To verify the hypothesis of ETS-1 functional shift, in
connection with P-T38 constitutive activation, we trea-
ted the primary Me1007 and the metastatic A375M
melanoma cell lines with the phorbol ester PMA, whi-
ch induces ETS-1 phosphorylation by stimulating
ERK1⁄2 through the RAF⁄MEK signaling pathway
(Jørgensen et al., 2005). Although at different levels and
with different kinetics, both PMA-treated cell lines
showed increased T38-ETS-1 phosphorylation coupled
with P-ERK expression levels (Figure 5A,B). In Me1007
cells displaying low endogenous levels of P-T38, PMA
induced a boost of phosphorylation as early as 10 min
after treatment, whereas in A375M cells, which already
displayed a high level of the phosphorylated fraction, a
signiﬁcant rise of P-T38 was observed only after 2 h. Of
note, unlike A375M, the Me1007 genome does not
carry any of the frequent mutations characterizing mela-
nomas, such as point mutations in N-RAS or B-RAF
genes. The levels of P-ERK and P-T38-ETS-1 were
always higher in A375M metastatic than in Me1007 pri-
mary melanomas (Figure 5A,B). The P-T38⁄total ETS-1
ratio might tune the ETS-1⁄miR-222 loop in melanoma,
a hypothesis that, beside promoter luciferase results,
appears to rely on the concordant increment of P-T38-
AB
CD
Figure 5. ETS-1 regulation in PMA-
treated melanoma cells. (A) Top,
representative WB analysis of P-T38 and
total ETS-1 expression in Me1007- and
A375M-treated cell lines as a paradigm of
primary and metastatic melanomas;
bottom, relative expression ratios, derived
from densitometric analysis, shown by
graph bars. (B) Top, representative WB
analysis and relative densitometric values
of P-ERK and total ERK (bottom). (C)
qRT-PCR of miR-222 in the same PMA-
treated samples. RNU6 was used for
normalization. Values are mean ± SD
of three independent experiments.
*P < 0.05; **P < 0.001. (D)
Representative WB analysis and relative
quantiﬁcation of c-JUN.
Mattia et al.
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melanomas (Figure 5A,B) and on the direct correlation
between the endogenously produced P-T38-ETS-1 and
miR-222 in melanoma progression. The well known
interplay already described between ETS-1 and c-JUN
also appears to be functional to miR-222 regulation. In
metastatic melanoma, the P-T38-activated fraction of
c-ETS-1, by competing with c-ETS-1 for binding to DNA,
may increase AP-1-driven transcription of those targets,
such as miR-222, containing ETS-1 and AP-1 binding
sites in close proximity on their promoters. Moreover,
as reported (Goldberg et al., 1994) and conﬁrmed by our
small interfering experiments showing c-JUN upregula-
tion in Dsi-ETS-1-transfected melanoma cells (results
not shown), c-ETS-1 is able to repress c-JUN, interfering
with its strong transcriptional regulation. Indeed, miR-
222 is barely detectable in the presence of a low
P-T38⁄total ETS-1 ratio and a low c-JUN level, and vice
versa (Figures 3A and 5A,B,D).
Functional role of ETS-1
To assess the functional role of ETS-1 in miR-222 regu-
lation and disease progression, we tested the tumori-
genic properties of melanoma cells forced either to
overexpress or repress ETS-1. The Me665⁄2 metastatic
melanoma, displaying a very low level of endogenous
ETS-1, was transduced with the Tween-lentiviral vector
overexpressing ETS-1. Although qReal time RT-PCR and
Western blot analyses conﬁrmed the correct transcrip-
tion and translation of the transduced ETS-1 cDNA, no
signiﬁcant increase of nuclear ETS-1 protein was
induced, most of the ectopically expressed ETS-1 being
delocalized in the cytoplasm (Supporting Information
Figure S3A). This result suggests that the nuclear shift
of ETS-1 is highly regulated in malignant melanoma
cells.
Clearer, although complex, results were obtained in
ETS-1 competition⁄repression experiments by using a
stable trans-dominant negative form (TM) or a transient
speciﬁc Dsi-ETS-1. The TM-truncated form of ETS-1,
containing only its binding domain, has been shown pre-
viously to compete with the wild-type protein for
the DNA binding sites and the underlying functions
(Figure S3B, left) (Nakano et al., 2000; Pourtier-Manzanedo
et al., 2003). This truncated form of ETS-1 was mainly
localized in the nucleus (Figure S3A). Six separate gene
transductions (TM1–TM6) were performed in the meta-
static melanoma A375M, and the A375M⁄TM4 mela-
noma cell line, selected for the highest amount of the
truncated protein, was successively utilized in most of
the functional analyses (Figure S3B, right). In vitro bio-
logical assays showed that TM-transduced cells prolifer-
ated slightly faster (20–30% increase) than the empty
vector-transduced counterpart (not shown) and dis-
played a 2.5-fold increase of invasive capacity, as evalu-
ated using a Boyden chamber assay (Figure 6A, left).
This invasive activity correlated with the amount of
TM expression, as shown by comparing A375M⁄TM4
and⁄TM5, with respectively high and low expression of
the dominant negative protein (Figure 6A, left). A signiﬁ-
cant enhancement (of approximately threefold) of mela-
noma capacities of forming foci in agar semisolid
A
B
CD
Figure 6. ETS-1 functional role in A375M
metastatic melanoma. (A) Invasion assay
(left), and evaluation of the number of foci
in semisolid medium (right) in TM
(dominant negative)-expressing cells
versus controls. (B) In vivo studies in i.v.
injected athymic nude mice evaluated as
number of lung (left) and abdominal
(middle) metastases; miR-222 and p27
expression were also evaluated in liver
and kidney TM-derived metastases
compared with controls; lung and liver
metastases are indicated by arrows (right).
Data, shown as median ± SD, were
obtained from at least three independent
experiments. (C) Left, qRT-PCR evaluation
of ETS-1; right, invasion assay in A375M
Dsi-ETS-1-transfected cells. (D) qRT-PCR
of miR-222 in Dsi-ETS-1-transfected (left)
and TM-infected A375M cells (right).
RNU6 was used for normalization.
*P < 0.05; **P < 0.01.
ETS-1-miR-222 circuitry in metastatic melanoma
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pared with vector-transduced cells (Figure 6A, right).
Similar results were obtained in Dsi-ETS-1-transfected
Me665⁄1 metastatic cell line (Figure S4).
The behavior of control Tween- and TM4-transduced
A375M cells was also tested in vivo following intrave-
nous injection in natural killer (NK)- depleted athymic
nude mice. A signiﬁcant increase in the number of lung
metastases was generated by intravenous (i.v.) injection
of TM4- compared with Tween-transduced cells
(Figure 6B, left). Moreover, we observed TM4-induced
abdominal metastasis dissemination, mainly to liver and
kidney (Figure 6B). As expected, TM4-derived metasta-
ses displayed a signiﬁcant increase of miR-222 and a
correlated decrease of p27Kip compared with controls
(Figure 6B, right).
We then considered the possibility that this Ets-
dominant negative protein interferes with other mem-
bers of the ETS family, although we never observed any
signiﬁcant modulation of ETS-2, the closest member to
ETS-1, in our melanoma samples (data not shown).
Nonetheless we cannot rule out the contribution of ETS
family proteins besides ETS-1 to melanoma functional
properties. To conﬁrm an ETS-1-speciﬁc contribution
unambiguously, we silenced it in A375M melanoma
cells using DsiRNA, obtaining a 75% downregulation of
ETS-1 as evaluated by qRT-PCR (Figure 6C, left) and
Western blot (Figure S3C). Although the effect of ETS-1
knockdown on cellular invasion (Figure 6C, right) was
less than that of TM (Figure 6A, left), results clearly con-
ﬁrmed a role of ETS-1 among all the ETS family genes
possibly targeted by the TM dominant negative. The
abrogation of ETS-1 mRNA and, even more, the expres-
sion of ETS-TM dominant negative were paralleled by a
signiﬁcant increase of miR-222, suggesting that both
the DsiETS-1 and the TM protein were able to unblock
miR-222 regulatory region by abrogating or competing
with the serine phosphorylated fraction or the amount
of unphosphorylated ETS-1 (Figure 6D and Supporting
Information Figure S4).
Finally, bearing in mind that our previous data
showed that the absence of PLZF underlies melanoma
progression by unblocking miR-221⁄-222 transcription,
we evaluated the possibility of an ETS-1⁄PLZF inte-
grated function. For this, we have speciﬁcally silenced
ETS-1 in control and PLZF-transduced A375M cells to
evaluate miR-222 expression levels and invasion capabil-
ities. As shown (Figures 6C,D and Supporting Informa-
tion Figure S5), we conﬁrmed a Dsi-ETS-1-dependent
increase of miR-222 paralleled by an enhanced invasion.
The presence of PLZF reduces the invasion capacity of
approximately 60% with respect to the control A375M
cell line, whereas the simultaneous abrogation of ETS-1
in A375M⁄PLZF⁄Dsi-ETS-1 transfected cells decreases
this PLZF-dependent inhibition thus suggesting that
ETS-1 is necessary for maximal PLZF suppressive
effects.
Discussion
MicroRNAs (miR) are non-coding small sequences that
regulate gene expression by binding to the 3¢UTRs of
their target mRNAs (Calin and Croce, 2006). Growing evi-
dence indicates that miRs are abnormally expressed in all
types of cancer, where they act as either oncogenes or
tumor suppressors (Voorhoeve, 2010). In addition, micr-
oRNA signatures have appeared as a new important
parameter which will hopefully allow, in the not too dis-
tant future, the selection of a truly tailored therapy based
on predicted risks (Galasso et al., 2010). In particular,
miR-221 and -222 are among the microRNAs most impli-
cated in cancer on the basis of their upregulation in a
number of solid tumors (Di Leva et al., 2010; Galardi
et al., 2007; Gillies and Lorimer, 2007; Medina et al.,
2008; le Sage et al., 2007). Croce and his group (2009)
described an increase of miR-221 and -222 in NSCLC and
HCC through c-JUN induction and PTEN and TIMP3
tumor-suppressor targeting (Garofalo et al., 2009). We
have described miR-221 and -222 upregulation in melano-
mas and their targeted repression of p27Kip and c-KIT
receptors, responsible for enhanced proliferation and
blockage of differentiation, respectively (Felicetti et al.,
2008). Here we have identiﬁed ETS-1 as another gene
directly regulated by miR-222, but not by miR-221, dem-
onstrating the existence of miR-221⁄-222-independent
functionalities, in addition to the common ones, as
recently reported for miR-222 in inﬂammation-mediated
neovascularization through STAT5A (Dentelli et al., 2010).
As reported (Filipowicz et al., 2008), the biological activi-
ties played exclusively by miR-221 or -222 should rely on
the differences in the nucleotide sequence, apart of the
seed, which can improve or reduce site efﬁcacy. Despite
sharing the same seed sequence (nt 2–8), nucleotides
13–16, which seem to play a signiﬁcant role in microRNA
function, are quite different in miR-221 and -222.
ETS-1 transcription factor is the founding member of
the ETS gene superfamily, encoding a class of phospho-
proteins characterized by a conserved domain that rec-
ognizes and binds to a GGAA⁄T DNA core sequence.
ETS-1 is involved in an array of cellular functions, acting
either as a positive or a negative regulator (He et al.,
2007; Nakayama et al., 1999). The presence of ETS-1 in
tissues derived from the neural crest, as melanocytes,
might suggest the association of ETS-1 downregulation
with the loss of the neural crest-associated phenotype
during melanoma progression; nevertheless, our data
speak in favor of its role in tumorigenesis. Of interest is
also the similarity between ETS-1 and c-KIT. Like ETS-1,
c-KIT is directly targeted by miR-221⁄-222 (Felicetti
et al., 2008), being involved in normal cell growth and
differentiation and repressed in metastatic melanomas
(Alexeev and Yoon, 2006; Huang et al., 1998).
Although ETS-1 gene expression correlates with pro-
gression of tumors such as thyroid, pancreas, liver,
lung and breast carcinomas (Seth and Watson, 2005),
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et al., 2004; Torlakovic et al., 2004).
Our results, showing miR-222-induced downregulation
of ETS-1 during melanoma progression, at ﬁrst sight
speak against a possible tumorigenic role of ETS-1. To
obtain a more realistic interpretation, we considered
ETS-1 post-translational modiﬁcations, rather than its
total protein content, functionally relevant to melanoma.
In particular, a signiﬁcant role should be played by the
T38-phosphorylated fraction of ETS-1 and, more speciﬁ-
cally, by the ratio of P-T38 and the total amount of ETS-1
protein, downstream to the RAS⁄RAF⁄MAPK pathway
(Grenningloh et al., 2008; Pufall et al., 2005).
This ETS-1 complex regulation might possibly explain
the controversial data describing ETS-1 as either directly
involved in determining the malignant phenotype (Roth-
hammer et al., 2004) or a useless marker unable to dis-
tinguish between benign and malignant melanocytic
lesions (Torlakovic et al., 2004). Torlakovic and collabora-
tors (2004) analyzed a large collection of nevi, primary
and metastatic melanomas from their archives for ETS-1
expression. They showed ETS-1 downregulation associ-
ated with tumor progression, with an inverse correlation
between its expression and melanoma dimension, but
no correlation with the tumor thicknesses. Further anal-
yses of post-transcriptional and⁄or post-translational
modiﬁcations, as well as of ETS-1 topographic cell distri-
bution, might clarify this issue.
Indeed, in melanoma ETS-1 has a deﬁnitely more com-
plex role than the apparent tumor-suppressive one, sim-
ply based on its downregulated expression in advanced
tumors. In fact, melanoma malignancy is associated more
with the RAS⁄RAF⁄ERK constitutive activation of ETS-1
than with ETS-1 total quantity, which also includes vari-
able amounts of unphosphorylated or serine-phosphory-
lated fractions. Speciﬁcally, we have shown that primary
melanomas display signiﬁcant amounts of ETS-1, barely
or not phosphorylated at T38, whereas metastatic cells
show the reverse pattern, with low levels of ETS-1 highly
phosphorylated at T38. This difference was particularly
evident when nuclear proteins were compared (see Fig-
ure 2B,C). A similar regulation has been shown in Ki-RAS-
transformed prostate cells where the activation of the
RAF⁄MEK⁄ERK signaling pathway induces ETS-1 phos-
phorylation at T38, nuclear translocation and tumor pro-
gression (Cho et al., 2008; Mylona et al., 2006). In
addition, the expression of miR-221 and miR-222 has
been reported to be under the positive control of the
RAS-MAPK signaling pathway in myoblasts induced to
differentiate and in post-mitotic myotubes (Cardinali
et al., 2009) and in PC12 cells (Terasawa et al., 2009).
Our results might ﬁll the gap between MAPK and
miR-222, demonstrating P-T38-ETS-1 protein as an inter-
mediate transcriptional regulator.
Considering that in non-small cell lung cancer and
hepatocarcinoma cells c-JUN has been involved in miR-
221⁄-222 activation (Garofalo et al., 2009), it is also
important to point out the capability of ETS-1 to associ-
ate and cooperatively bind with the AP-1 transcription
complex to regulate gene expression (Chang et al.,
2003). Our data conﬁrm that, in metastatic melanomas,
the ERK constitutive signaling activates c-JUN (Lopez-
Bergami et al., 2007) and P-T38-ETS-1 (Yang et al.,
1996), which in turn seem to cooperate towards
miR-221⁄-222 activation (Figure 5) (Garofalo et al.,
2009). Of note, the increment of miR-222 observed in
the A375M metastatic melanoma after a 2-h PMA treat-
ment was coupled with a simultaneous activation of
P-T38-ETS-1, whereas the constitutive high expression
of c-JUN appeared unmodiﬁed, thus suggesting that a
higher P-T38⁄ETS-1 ratio is an essential step for miR-
222 regulation and, consequently, melanoma malig-
nancy (Figure 5). Finally, it is important to mention the
intriguing results obtained by transducing the dominant
negative TM ETS-1 in the A375M and Me665⁄1 melano-
mas in that it induces a more aggressive behavior with
respect to control cells both in vitro and in vivo. The
increased levels of miR-222 and, in turn, of tumorigene-
sis induced by the dominant negative truncated form of
ETS-1 is probably derived from the competitive displace-
ment of the inhibitory components of this protein.
Considering that opposite functions of ETS-1 have been
already described and linked to the different biological
contexts (Sato et al., 2001), it is likely that in melanoma
cells the net establishment of a more aggressive pheno-
type could derive from undermining the nuclear unphos-
phorylated and, even more, the serine-phosphorylated
ETS-1 fractions characterized by a signiﬁcantly lower
DNA afﬁnity (Pufall et al., 2005). In this picture, the
TM-dependent invasive potential of the A375M cells in
nude mice (a more than ﬁvefold increase in the number
of lung metastases and dissemination to additional
areas) seems, at least in part, the consequence of the
enhanced miR-222 expression coupled with targeted
repression of tumor suppressors such as p27Kip (Fig-
ure 6). Nonetheless, TM ETS-1 might also compete with
other ETS-1-regulated tumor suppressor genes, such as
DUSP6 in lung cancer (Zhang et al., 2010).
Taken together, our data suggest a complex ETS-
1⁄miR-222 coregulatory loop where the balance
between miR-222 and this target is differentially modu-
lated in normal and neoplastic cells. Indeed, ETS-1 loses
its normal repressive function in melanoma, becoming a
positive regulator of miR-222. This is a consequence of
MAPK constitutive activation leading to high levels of
P-T38, the ETS-1-activated form that seems to coopera-
tively act with PLZF and c-JUN as ﬁne-tuners of
miR-222. In this context, high c-JUN expression should
be considered a necessary, but not sufﬁcient, step.
Moreover, ETS-1 expression seems to be required for
effective PLZF repression (Figure S5). Conversely, P-Ser
and unphosphorylated ETS-1 molecules should downre-
gulate c-JUN (results not shown). Finally, it is important
to consider that such a complex regulation, being just a
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ETS-1, underscores the importance of further analyses
absolutely required before any possible translation to
therapy. These data represent another piece of evidence
substantiating the inhibition of miR-221 and -222 as a
promising approach for translation to the clinical setting
by restoring the underlying signaling pathways.
Methods
Cell lines culture and transduction
Most of the human melanoma cell lines used in the cur-
rent study was stabilized from surgical specimens
obtained from primary or metastatic tumors at Istituto
Nazionale Tumori in Milan (Italy). Cell lines were charac-
terized for growth in soft agar and, whenever possible,
their metastatic potential was evaluated in athymic nude
mice. Stages and references of these cell lines are
listed in Care ` et al. (1996). The A375 cell line was from
the American Type Tissue Collection (Rockville, MD)
and its metastatic variant A375M was kindly provided
by Dr. R. Giavazzi (Istituto M. Negri, Bergamo). Normal
human epidermal melanocytes from foreskin were
obtained from Promocell (Heidelberg, Germany).
To modulate ERK1⁄2 activity, melanoma cells were
treated with 50 nM of phorbol-12-myristate-13-acetate
(PMA) at 37 C up to 2 h (Jørgensen et al., 2005).
The ETS-1 cDNA, encompassing its complete coding
sequence, and the ETS-1 transdominant negative
mutant TM were cloned in the retroviral Pinco and the
lentiviral Tween vectors, respectively (Lulli et al., 2010).
Overexpression of PLZF and miR-221⁄-222 were
obtained in melanoma cells by using retroviral and len-
tiviral vector systems, as reported (Felicetti et al., 2008).
‘Controls’ are always designed as empty vector-
transduced cell lines.
ETS-1 was speciﬁcally silenced using small interfering
RNA (IDT, Leuven, Belgium). Brieﬂy, 24 h after plating,
cells were transfected using Lipofectamine 2000 (Invitro-
gen srl, San Giuliano Milanese, MI, Italia) with either
DsiETS-1 (HSC.RNAI.N001143820.10.1) or a DsiRNA
scrambled control (ﬁnal concentration 200 nM). The level
of ETS-1 mRNA was analyzed 48 h after transfection
by qReal-time PCR (Applied Biosystems assay
#Hs00428287, Life Technologies Corporation, Carlsbad,
CA, USA) and the functional properties of the cells evalu-
ated uptoday 5.
MicroRNA-221 and -222 silencing by antagomir
treatment
Chemically modiﬁed antisense oligonucleotides (antago-
mir) were used to inhibit miR expression in vitro and
in vivo. The sequences of antagomir-221 and antagomir-
222 used were 5¢P-GAAACCCAGCAGACAAUGUAGCU-
3¢-Chl and 5¢P-GAGACCCAGUAGCCAGAUGUAGCU-3¢-
Chl, respectively; all the bases were 2¢-OMe-modiﬁed.
Antagomir oligonucleotides (Dharmacon Inc., Lafayette,
CO, USA), were transfected at doses ranging from 50
to 200 nM using Fugene HD (Roche Diagnostics Spa,
Monza, MI, Italia), according to the manufacturer’s pro-
cedures. As controls, an unrelated antagomir (speciﬁ-
cally the antagomir targeting miR-133a that is not
expressed in melanomas) and an FITC-conjugated oligo
targeting the luciferase sequence (ratio FITC oligo:antag-
omir 1:10) were transfected as well. Transfection
efﬁciencies were analyzed by FACS.
Western blot
Western blot was performed according to standard pro-
cedures. Cell lysates were separated by the pre-cast
NuPAGE polyacrylamide gel system (Invitrogen). Antibodies
against ETS-1 (anti-rabbit from Santa Cruz Biotechnology,
Santa Cruz, CA, USA and anti-mouse from Novocastra,
Newcastle, UK), ETS-2 (Santa Cruz Biotechnology), ETS-
1-P-T38 and ETS-1-P-S282⁄285 (Biosource International
Inc., Camarillo, CA, USA), c- JUN (Santa Cruz Biotechnol-
ogy) ERK1⁄2, P-ERK1⁄2 and p27Kip1 (Cell Signaling Tech-
nology Danvers, MA, USA) were used in accordance with
the manufacturer’s instructions. Actin (Oncogene
Research, San Diego, CA, USA), tubulin (Sigma, St. Louis,
MO, USA) and nucleolin (Santa Cruz Biotechnology) were
used as controls for loading and speciﬁcity. The expres-
sion levels were evaluated by SCION IMAGE Software
(http://www.scioncorp.com).
Promoter luciferase assay
To analyze the functional roles of the two putative ETS
binding sites (indicated as BS1 and BS2 in Figure 4), a
DNA fragment containing the putative regulatory region
upstream to miR-222⁄-221 (from )555 to +1 nt) was
ampliﬁed and cloned in pGL3 basic (Promega, Madison,
WI, USA). A shorter construct (from )400 to +1 nt) con-
taining the sole BS1 was also prepared. 293FT, Me1007
or A375M cell lines were transfected with Lipofecta-
mine 2000 (Invitrogen) and (i) 200 ng of pGL3 basic or
pGL3 containing the above genomic fragments,
(ii) 150 ng of empty or ETS-1-expressing plasmid, and
(iii) 30 ng of Renilla. At 48 h, cells were lysed and their
luciferase activity measured using the FemtomasterFB
12 (Zylux, Huntsville, AL, USA). The wt pGL3 plasmids
cotransfected with the control vector were considered
to be 100%. As controls of speciﬁcity, point mutations
were inserted in the wild-type core-binding sequence
for ETS-1 using the QuickChange site-directed mutagen-
esis kit (Agilent Technologies, Santa Clara, CA, USA).
Bold letters indicate the core consensus sequence.
Mutated nucleotides are shown in lower case letters.
BS1: 5¢-TGCTGCgaGcTCTCCAG -3¢; BS2: 5¢-TGACt
GcAgGCAACA -3¢.
Chromatin immunoprecipitation (ChIP) assay
Five · 10
6 cells from A375M melanoma cell line were
ﬁxed in 1% formaldehyde for 10 min at room tempera-
ture. Cells were washed with ice cold 1· PBS, scraped
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trifugation. Cell pellets, resuspended in cell lysis buffer
(50 mM Tris–HCl pH 8.0, 10 mM EDTA, 1% SDS) in the
presence of protease inhibitors, were sonicated. DNA-
protein complexes were immunoprecipitated using 3 lg
of anti-ETS-1, anti-P-T38 or, as an internal control, the
unrelated anti-DVL-1 (Santa Cruz). DNA-protein cross-
links were reversed by heating at 65 C overnight. The
recovered DNAs were then PCR-ampliﬁed with the fol-
lowing primer set: DIR 5¢-GGATCTACACTGGCTACT-
GAG-3¢ and REV5¢-GTCACAAGGAATCATGTATGC-3¢,
corresponding to ETS- binding site at -203 (BS1); DIR5¢-
CAGCATACATGATTCCTTGTGA-3¢ and REV 5¢-CTTTGGT-
GTTTGAGATGTTTGG-3¢, ETS binding site at –407 (BS2).
Control ampliﬁcation was carried out on input chromatin
(preserved before immunoprecipitation) and on DVL-1
(mock)-immunoprecipitated chromatin. To conﬁrm the
speciﬁcity of the immunoprecipitated products, GAPDH
PCRs were also run.
In vivo assay
For the in vivo assays, empty vector- or TM-transduced
A375M cells in exponential growth phase were injected
subcutaneously (s.c.) and i.v. at the dose of 10
6 cells in
adult athymic nude mice, minimum n = 5 mice per group
(Charles River, Calco, Italy) pretreated with rat anti-
mouse mAb to interleukin (IL)-2Rb (TMb1, the kind gift of
Daniela Mannel, Regensburg, Germany) to deplete NK
cells. Tumor growths were monitored twice a week. Six
weeks after the injection, mice were sacriﬁced for nec-
ropsy and macroscopic metastases evaluation. Lung
metastases were counted under a stereomicroscope
after staining with India ink. Mice were treated and main-
tained at the Istituto Nazionale Tumori (Milan, Italy)
according to institutional guidelines.
Statistical analysis
Unless otherwise stated, results were representative of at
least three independent experiments. All data were pre-
sented as mean values ± standard deviation (SD) or stan-
dard errors (SE). Statistical analysis was performed using
the t-test with P > 0.05 deemed statistically signiﬁcant.
See alsoAppendix S1forsupplementary methods.
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Figure S1. Representative western blot of ETS-1 and
its P-T38 phosphorylated fraction in normal human
melanocytes (NHEM) and metastatic melanoma cell
lines.
Figure S2. A, Promoter luciferase assays obtained by
cotransfecting different genomic fragments (as indicated
in Figure 4A) in 293FT cells in presence or not of ETS-1.
As controls, mutations of core nucleotides have been
included. Data are representative of at least three inde-
pendent experiments. *P < 0.05. B, qRT-PCR analysis
at different time points of ETS-1 mRNA (left) and miR-
221/-222 (right). C, WB of ETS-1 and its P-T38-fraction,
ERK1/2 and P-ERK1/2 in ETS-1 transfected 293FT cells.
A375M is included as a positive control.
Figure S3. A, western blot analysis of ETS-1 and P-
T38-ETS-1 in stably infected Me665/2/ETS-1 and
A375M/TM4 melanoma cell lines compared with the
corresponding empty vector transduced cells. Nuclear
and cytoplasmic extracts have been analyzed. Actin is
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964 ª 2011 John Wiley & Sons A/Sshown as a loading control. B, left, schematic picture of
ETS-1 protein and its dominant negative (TM) truncated
form; right, WB analysis of TM-transduced-A375M (TM1
to TM6 represent six independent lentiviral infections).
C, western blot analysis showing ETS-1 downregulation
in Dsi-ETS-1 transfected A375M cells. Dsi-scrambled is
included as a negative control and actin is shown as a
loading control.
Figure S4. ETS-1 functional role in Me665/1 meta-
static melanoma. qRT-PCR of ETS-1 and miR-222 in
Dsi-ETS-1 transiently transfected Me665/1 cells (top).
GAPDH and RNU6 were used to normalize. Invasion
assay in the same Dsi-ETS-1 transfected cells (bottom).
*P < 0.05; **P < 0.01.
Figure S5. ETS-1/PLZF integrated function. qRT-PCR
of ETS-1 and miR-222 in Dsi-ETS-1 transiently trans-
fected A375M/PLZF cells (top). Relative invasion capabil-
ities of A375M control, A375M/PLZF and A375M/PLZF/
Dsi-ETS-1 cells (bottom). A Dsi-scrambled sequence
was included as a negative control. *P < 0.05;
**P < 0.01.
Figure S6. Schematic representation of ETS-1-miR-
222 regulatory circuitry in primary and metastatic mela-
nomas. In primary melanomas lacking signiﬁcant geno-
mic alterations, as Me1007, high levels of inactive not
phosphorylated ETS-1 repress miR-222 transcription.
Conversely, in metastatic cells, as A375M, the constitu-
tive activation of ERK1/2 induces ETS-1 phosphorylation
at Thr38 and activates miR-222, possibly in cooperation
with c-JUN. In turn, high amounts of miR-222 downre-
gulates ETS-1, sustaining a high P-T38/total ETS-1 ratio.
Appendix S1. Methods.
Please note: Wiley-Blackwell are not responsible for
the content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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